Merck & Co. reported mixed first-quarter 2014 results before markets opened Tuesday morning. The loss of market exclusivity continues to hurt the top line. Merck reaffirmed its forecast for the full year.
Paul Ausick The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it…
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of…
Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for the full year.
Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance also allowed sellers to keep exiting the…
thinkstockApril 9, 2014: Markets opened higher on Wednesday and then got a jolt higher following the afternoon release of the FOMC’s last meeting minutes. The minutes indicated to many investors and traders…
ThinkstockThe short interest data for the first two weeks of March is out, and the results among the top high-yield safe dividend stocks are mixed. The biggest changes took place in the…
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to the…
thinkstockMarch 25, 2014: Markets opened higher on Tuesday but dipped sharply in the late morning on weakness in consumer discretionary, financial, and biotech stocks. The Dow and the S&P 500 held on…
thinkstockMarch 24, 2014: Markets opened slightly higher on Monday but soon took a turn south and spent most of the day solidly down. Biotechs, healthcare, discretionary, and tech stocks were all weaker…
thinkstockMarch 21, 2014: Markets opened higher on Friday but the Nasdaq sank quickly, bounced for a while, and finally settled solidly lower. It took the Dow and the S&P 500 until noon…
Endocyte is trading like it is being acquired. This is proof that any biotech with great cancer drug news can run, regardless of market conditions. One has to wonder if Endocyte is…
Jon C. Ogg States, often burdened by budget deficits that grew during the recession, are not getting tax receipts from some of America's largest companies. Among them are Boeing and Merck, which did not pay…
ThinkstockThe short interest data for the final two weeks of February is out, and the results are somewhat surprising when it comes to the top high-yield safe dividends out there. Some of…
The pricier the stock market gets, the more important it is for investors to keep a close eye on what they are paying for stocks. Flashy momentum stocks are great for traders,…
